WHY KAIROS?

Unmet Medical Need

Drug

How Kairos Addresses Unmet Medical Need

Development of resistance to many, otherwise effective, cancer drugs (hormone based therapies, EGFR-based therapies, radiation, and other specific chemotherapies)

ENV 105

• ENV105 inhibits CD105  (CD105 is the protein responsible for cancer drug resistance in various forms of cancer)

• Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer

T cells drastically reduced by cancer

 

KROS 101

• KROS101 uses a novel dual mechanism to increase killer T cells and reduce suppressor T reg cells  (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response)

In autoimmune diseases, T cells are overactive against normal cells

KROS 102

• KROS102 has the opposite effect of KROS101, by decreasing the number  overactive T cells and increasing Treg suppressor cells

Immunosuppression from cancer

KROS 201

• KROS201 are  killer T cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth.

• Currently cleared for IND (investigational new drug application) by FDA

Chemotherapies are untargeted and immunosuppressive

KROS 301

• By targeting the NF-kB molecular pathway, KROS 301 aims to kill tumors and inhibit the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer)

Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer)

KROS 401

• KROS401 targets pro-cancer macrophages to convert them into anti-cancer macrophages

Development of resistance to various specific chemotherapies

ENV 205

• ENV205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies
For more scientific explanations and references press here

Investment highlights

  •  Three ongoing clinical programs
    • Phase 2 trial treating Prostate Cancer with NIH grant funding
    • Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded
    • Cleared IND for Glioblastoma
  • Strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally in 2022-2023 US News and World Report) enhances clinical trial efficiency (costs and enrollment) and streamlines therapeutic innovation
  • Initial clinical development focuses on overcoming cancer drug resistance derisked with extensive safety studies and biomarker for potential response
  • Extensive therapies to reverse immune suppression in our pipeline
  • Extensive IP portfolio valid until 2035 to 2040
  • Our technologies target a high value, large market - targeting a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market